MDR planning · manufacturer readiness · notified-body review
How long does CE marking take?
The honest answer is not one number. It is one critical path.
CE marking has no universal statutory duration. The calendar is built from product development, evidence generation, QMS implementation, notified-body availability, assessment cycles and the time needed to close questions.
Build a realistic timeline ↓Rule 01 A launch date without a readiness model is only a wish.
The short answer
Start by asking which clock dominates
A device that is technically finished but clinically under-supported is not “almost ready.” Neither is a polished dossier attached to an immature QMS.
Standard class I, genuinely ready
No notified-body certificate is required. If development, verification, clinical evaluation, technical documentation and the QMS are already complete, final regulatory assembly may take weeks to a few months.
A route requiring notified-body certification
Manufacturer preparation comes first. After the written agreement, the latest EU survey shows that most MDR certification routes still occupy a further 13–24 months, depending on certificate scope.
A device that still needs pivotal evidence
Biocompatibility, electrical safety, software validation, usability work or a clinical investigation can become the critical path. Certification cannot compress evidence that has not yet been generated.
Calendar time = manufacturer preparation + contracting + active assessment + pauses + final release
The critical path
Six clocks can run, but not all can run in parallel
A useful timeline is dependency-based. It shows what must finish before the next activity can start and which workstreams can proceed together.
Intended purpose and classification
The route cannot be priced or planned reliably until the device and its claims are stable.
Verification, validation and clinical evidence
Testing lead times, sample availability and clinical follow-up often determine the real project duration.
QMS implementation and records
A procedure written yesterday is not automatically an implemented process with auditable evidence.
Technical documentation
The dossier should tell one consistent story across risk, clinical evidence, design controls and labelling.
Notified-body contracting and review
Scope acceptance, audit, product review, questions and nonconformity closure create an external clock.
Declaration, CE mark and registrations
The manufacturer affixes the CE mark after the applicable conformity assessment and release controls are complete.
What the latest data say
The certificate clock is still measured in months, not sprints
The European Commission’s 20th notified-body survey reports the time from signed written agreement to issuance of a new MDR certificate, with data status 28 February 2026.
of reporting notified bodies fell in the 6–18 month bands.
fell in the 13–24 month bands.
Manufacturer preparation before the written agreement sits outside these figures.
These are observed bands reported by notified bodies, not legal deadlines and not a prediction for a particular device. View the Commission-published survey ↗
The 2027 rulebook
New maximum phases will make the active clock more predictable
Commission Implementing Regulation (EU) 2026/977 applies from 25 February 2027. It sets maximum phases for notified-body conformity assessment, but it does not create one universal deadline for CE marking.
Complete application review and contract
The phase begins when the notified body receives a complete application and ends when the contract is signed.
QMS auditing
From the first audit-programme activity through completion of the notified body’s final review.
Product verification
From initiation of technical-documentation assessment through completion of the relevant final review.
Decision and certification
From the day after the final relevant review to certificate issuance and entry in EUDAMED.
For a straightforward Annex IX path with parallel QMS and product activities, that arithmetic describes the maximum active phases. It still excludes pre-application work, manufacturer preparation and clock interruptions. It is not a 170-calendar-day promise.
The pause button
Why active assessment days become a longer calendar
The 2027 rules expressly allow interruption of the assessment clock. The most effective schedule control is therefore faster, better-quality closure of questions.
Incomplete starting package
The 30-day application phase starts only after a complete application has been received.
Questions and nonconformities
The clock may pause while the manufacturer prepares evidence, corrections or a corrective-action plan.
External consultation
EMA, a regulatory authority, an expert panel or an EU reference laboratory can introduce an additional interruption.
Evidence or design change
A weak response can reveal a deeper gap, triggering new testing, clinical work or dossier realignment.
Sites and critical suppliers
Additional manufacturing sites, outsourced processes and audit logistics can expand assessment work and coordination.
Release-tail activities
Translations, UDI data, EUDAMED entries, authorised-representative coordination and controlled release still need owners.
The class I myth
No notified body does not mean no regulatory work
For standard class I devices, the manufacturer normally performs conformity assessment without notified-body certification. The shortcut is only the missing third-party assessment—not the disappearance of MDR obligations.
Class I devices supplied sterile, devices with a measuring function and reusable surgical instruments require notified-body involvement limited to the relevant special aspects.
- 01Intended purpose and justified classification
- 02GSPR evidence and risk management
- 03Clinical evaluation and applicable testing
- 04Technical documentation and controlled labelling
- 05Proportionate QMS, UDI and EUDAMED data
- 06EU declaration of conformity and post-market system
Planning method
Shorten the route by removing rework, not controls
The fastest defensible programme is usually the one that finds contradictions before the notified body does.
Freeze the regulatory identity
Align intended purpose, claims, user, patient population, operating principle and classification before detailed dossier drafting.
Build an evidence map
Connect every relevant GSPR and risk control to a test, standard, clinical source or documented justification.
Run QMS and dossier work together
Use live development records to demonstrate implementation rather than writing procedures after the product is finished.
Approach suitable notified bodies early
Confirm designation scope, technology fit, sites, certificate needs and application expectations before the target submission date.
Conduct a consistency review
Challenge clinical claims, risk controls, specifications, test reports, IFU and marketing language as one connected evidence system.
Prepare the response room
Assign decision owners, evidence owners and response deadlines before the first question or nonconformity arrives.
Practical questions
Four timeline traps to avoid
A date becomes useful only after its assumptions are visible.
Can we CE-mark a medical device in three months?+
Possibly for a standard class I device when development, testing, clinical evaluation, technical documentation and the QMS are already complete. It is generally not a realistic end-to-end assumption for a route requiring notified-body certification.
Does every class I device avoid notified-body assessment?+
No. Notified-body involvement is required for class I devices supplied sterile, devices with a measuring function and reusable surgical instruments. The assessment is limited to the applicable special aspects.
Does the 120-day QMS limit mean a certificate in 120 days?+
No. It is one active phase under the rules applying from 25 February 2027. Application review, product verification where required, decision and certification are separate, and assessment clocks may be interrupted.
When should we contact a notified body?+
Once the intended purpose, classification, technology, sites and conformity-assessment route are sufficiently stable to describe the scope accurately. Do not wait for a “perfect” dossier before checking scope and application expectations.
Primary references
Official sources used for this timeline
From target date to controlled plan
Need a CE-marking timeline that reflects your actual device?
We can turn the intended purpose, risk class, evidence gaps, QMS status and conformity-assessment route into a dependency-based programme.
